Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US69329Y1047
Ticker PDLI
Company PDL BIOPHARMA
Currency $
Price
Aware Investor Index (AII) 38.8085
Recommendation STRONG BUY
P/E 2.39
ROE 21.93 %
Capitalization 443,769,880 $
Dividend Yield 0.00 %
P/S 1.39
AII Position 51
P/E Position 2
ROE Position 134
Capitalization Position 722
Dividend Yield Position 595
Sales 320,060,000 $
10-Year Average Earnings 185,490,200 $
Shares Outstanding 156,257,000
Equity 845,890,000 $
Dividend per Share 0 $
Industry Biotechnology
Country United States
PDL BIOPHARMA Investor Relations Web Site http://investor.pdl.com







Sales:

YEAR MONTH AMOUNT
2017 12 320,060,000.00 $
2016 12 244,301,000.00 $
2015 12 590,448,000.00 $
2014 12 581,225,000.00 $
2013 12 442,921,000.00 $

Earnings:

YEAR MONTH AMOUNT
2017 12 110,748,000.00 $
2016 12 63,606,000.00 $
2015 12 332,795,000.00 $
2014 12 322,244,000.00 $
2013 12 264,530,000.00 $
2012 12 211,669,000.00 $
2011 12 199,389,000.00 $
2010 12 91,874,000.00 $
2009 12 189,660,000.00 $
2008 12 68,387,000.00 $

Equity:

YEAR MONTH AMOUNT
2017 12 845,890,000.00 $
2016 12 755,423,000.00 $
2015 12 695,952,000.00 $
2014 12 460,437,000.00 $
2013 12 113,489,000.00 $
2012 12 -68,122,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 156,257,000
2016 12 164,192,000
2015 12 163,554,000
2014 12 173,110,000
2013 12 159,343,000
2012 12 146,403,000

 












Bloomberg News for PDL BIOPHARMA:



Google News for PDL BIOPHARMA:

NMSU Nеws - 1 hour ago
Becoming More Capital Intensive? Navient Corporation (NAVI), PDL ...
Navient Corporation (NAVI), PDL BioPharma, Inc. (PDLI) ... The current market cap of PDL BioPharma, Inc. is valued at $424.52M. The value ...
Hawthorn Caller
PDL BioPharma (PDLI) Q3 Earnings Top, Revenues Rise, Stock Up
Shares of PDL BioPharma were up almost 18% following its earnings release on Nov 6. In fact, the stock has gained 5.9% so far this year ...
Talk Traders (press release) (blog)
Favorable Time to Sell on PDL BioPharma, Inc. (PDLI)? RSI 64.86 ...
Favorable Time to Sell on PDL BioPharma, Inc. (PDLI)? RSI 64.86 signals ... PDLI reported a change of 14.06% over the last week and ...
Wallstreet Investorplace
PDL BioPharma Inc (PDLI) Expected to Post Earnings of $0.08 Per ...
Wall Street brokerages expect PDL BioPharma Inc (NASDAQ:PDLI) to post $0.08 earnings per share (EPS) for the current quarter, Zacks ...
Zacks.com - 5 days ago
Head to Head Review: PDL BioPharma (PDLI) versus Arsanis (ASNS)
PDL BioPharma (NASDAQ:PDLI) and Arsanis (NASDAQ:ASNS) are both small-cap medical companies, but which is the better business?
Financial Mercury
Avg. Price Target Review: PDL BioPharma (PDLI) to Hit $3 in short ...
PDL BioPharma (PDLI) stock managed performance 14.06% over the last week and switched with performance of 12.25% throughout past one month period.
NMSU Nеws
PDL BioPharma Inc. (PDLI) CEO John McLaughlin on Q3 2018 ...
PDL BioPharma, Inc. (NASDAQ:PDLI) Q3 2018 Results Earnings Conference Call November 6, 2018 4:30 PM ET. Executives. Jody Cain ...
The RNS Daily
PDL BioPharma (PDLI) Trading 0.7% Higher
Shares of PDL BioPharma Inc (NASDAQ:PDLI) were up 0.7% during mid-day trading on Thursday . The company traded as high as $2.96 and ...
Wall Street Morning - 4 hours ago
Pdl Biopharma Inc (PDLI) Run Higher 15.32% For the Week
Pdl Biopharma Inc (PDLI) have climbed higher over the course of the past week revealing positive upward momentum for the shares. In taking ...
Fairfield Current - 1 day ago
PDL BioPharma beats by $0.02, beats on revenue
PDL BioPharma (NASDAQ:PDLI): Q3 Non-GAAP EPS of $0.09 beats by $0.02; GAAP EPS of $0.18 beats by $0.11. Revenue of $67.9M (+8.2% ...


Back